Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1821586 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $18.71Day −5.89%Mkt cap $1.4B1Y −65.7%Off 52W high −70.2%Vol (1Y) 119.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,009 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest8.6% of sh out |
| Days to cover5.0d |
| 13F net flow (QoQ)+3.79% |
| Top-10 13F concentration63.9% |
| Next report (est.)2026-08-11 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$257.1M |
| ROE−60.5% |
| ROIC−122.0% |
| Debt / equity0.24× |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+42.0% |
| 1Y−65.7% |
| 3Y−69.5% |
| Since incept. (ann.)+36.0% |
Total return through 2026-07-28 · series begins 2022-07-13. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)119.0% |
| Ann. volatility (3Y)83.4% |
| Sharpe (1Y)0.51 |
| Sharpe (3Y)0.34 |
| Max drawdown (1Y)−89.9% |
| Max drawdown (3Y)−90.2% |
| Beta (3Y vs SPY)0.07 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BVF INC/IL | 16.0M | $298M | 21.74% | −19.0% |
| Deep Track Capital, LP | 6.4M | $119M | 8.71% | +39.0% |
| Cormorant Asset Management, LP | 4.5M | $84M | 6.09% | +2.9% |
| JANUS HENDERSON GROUP PLC | 3.5M | $64M | 4.69% | +64.7% |
| D. E. Shaw & Co., Inc. | 2.4M | $45M | 3.25% | −3.6% |
| MPM BIOIMPACT LLC | 1.8M | $34M | 2.46% | new |
| Weiss Asset Management LP | 1.7M | $32M | 2.32% | +413.1% |
| Logos Global Management LP | 1.5M | $28M | 2.04% | −14.3% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$0.98 | — | — | — |
| 2025-09-30 | 2025-11-05 | −$1.10 | — | — | — |
| 2025-06-30 | 2025-08-05 | −$0.87 | — | — | — |
| 2025-03-31 | 2025-05-12 | −$0.63 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-11 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
